Dysplasia and risk of further neoplastic progression in a regional veterans administration Barrett's cohort

American Journal of Gastroenterology

Volumn 100, Issue 4, 2005, Pages 775-783

  Dulai, Gareth S ^a   Shekelle, Paul G ^b   Jensen, Dennis M ^b   Spiegel, Brennan M R ^b   Chen, Jaime ^b   Oh, David ^b   Kahn, Katherine L ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER GROWTH; CANCER INCIDENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; DYSPLASIA; ESOPHAGOSCOPY; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; HEALTH CARE SYSTEM; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME; ADENOCARCINOMA; BIOPSY; CELL TRANSFORMATION; CLINICAL TRIAL; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; ESOPHAGUS; ESOPHAGUS TUMOR; HEALTH SURVEY; INCIDENCE; INFORMATION PROCESSING; INTEGRATED HEALTH CARE SYSTEM; MEDICAL RECORD; METAPLASIA; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PRECANCER; PUBLIC HOSPITAL; RISK FACTOR; STATISTICS; UNITED STATES;

ADENOCARCINOMA; AGED; BARRETT ESOPHAGUS; BIOPSY; CALIFORNIA; CELL TRANSFORMATION, NEOPLASTIC; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DATA COLLECTION; DELIVERY OF HEALTH CARE, INTEGRATED; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; ESOPHAGUS; FOLLOW-UP STUDIES; HOSPITALS, VETERANS; HUMANS; INCIDENCE; MALE; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; METAPLASIA; MIDDLE AGED; POPULATION SURVEILLANCE; PRECANCEROUS CONDITIONS; RISK FACTORS;

EID: 17544377741     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.41300.x     Document Type: Article

References (50)

1. Shaheen N, Ransohoff DF. Gastroesophageal reflux, barrett esophagus, and esophageal cancer: Scientific review. JAMA 2002;287:1972-81.
2. Falk GW. Barrett's esophagus. Gastroenterology 2002;122:1569-91.
3. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002;97:1888-95.
4. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: A new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999;94:2043-53.
5. Inadomi JM, Sampliner R, Lagergren J, et al. Screening and surveillance for Barrett esophagus in high-risk groups: A cost-utility analysis. Ann Intern Med 2003;138:176-86.
6. Shaheen NJ, Crosby MA, Bozymski EM, et al. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? (see comments). Gastroenterology 2000;119:333-38.
7. Hamilton SR, Smith RR. The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett's esophagus. Am J Clin Pathol 1987;87:301-12.
8. Skinner DB, Walther BC, Riddell RH, et al. Barrett's esophagus. Comparison of benign and malignant cases. Ann Surg 1983;198:554-65.
9. Haggitt RC, Tryzelaar J, Ellis FH, et al. Adenocarcinoma complicating columnar epithelium-lined (Barrett's) esophagus. Am J Clin Pathol 1978;70:1-5.
10. Robertson CS, Mayberry JF, Nicholson DA, et al. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus. Br J Surg 1988;75:760-3.
11. Hameeteman W, Tytgat GN, Houthoff HJ, et al. Barrett's esophagus: Development of dysplasia and adenocarcinoma (see comments). Gastroenterology. 1989;96:1249-56.
12. Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus (see comments). Gut. 1991;32:1441-46.
13. Iftikhar SY, James PD, Steele RJ, et al. Length of Barrett's oesophagus: An important factor in the development of dysplasia and adenocarcinoma (see comments). Gut 1992;33:1155-58.
14. O'Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: Report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 1999;94:2037-42.
15. Weston AP, Badr AS, Hassanein RS. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma (see comments). Am J Gastroenterol 1999;94:3413-19.
16. Skacel M, Petras RE, Gramlich TL, et al. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol 2000;95:3383-87.
17. Reid BJ, Levine DS, Longton G, et al. Predictors of progression to cancer in Barrett's esophagus: Baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000;95:1669-76.
18. Weston AP, Banerjee SK, Sharma P, et al. p53 protein over-expression in low grade dysplasia (LGD) in Barrett's esophagus: Immunohistochemical marker predictive of progression. Am J Gastroenterol 2001;96:1355-62.
19. Gopal DV, Lieberman DA, Magaret N, et al. Risk factors for dysplasia in patients with Barrett's esophagus (BE): Results from a multicenter consortium. Dig Dis Sci 2003;48:1537-41.
20. Murray L, Watson P, Johnston B, et al. Risk of adenocarcinoma in Barrett's oesophagus: Population based study. Br Med J 2003;327:534-35.
21. Haggitt RC, Reid BJ, Rabinovitch PS, et al. Barrett's esophagus. Correlation between mucin histochemistry, flow cytometry, and histologic diagnosis for predicting increased cancer risk. Am J Pathol 1988;131:53-61.
22. Reid BJ, Blount PL, Rubin CE, et al. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: Prospective endoscopic surveillance of a cohort (see comments). Gastroenterology 1992;102:1212-19.
23. Fennerty MB, Sampliner RE, Way D, et al. Discordance between flow cytometric abnormalities and dysplasia in Barrett's esophagus (see comments). Gastroenterology 1989;97:815-20.
24. Menke-Pluymers MB, Mulder AH, Hop WC, et al. Dysplasia and aneuploidy as markers of malignant degeneration in Barrett's oesophagus. The Rotterdam Oesophageal Tumour Study Group. Gut 1994;35:1348-51.
25. Montgomery EA, Hartmann DP, Carr NJ, et al. Barrett esophagus with dysplasia. Flow cytometric DNA analysis of routine, paraffin-embedded mucosal biopsies. Am J Clin Pathol 1996;106:298-304.
26. Teodori L, Gohde W, Persiani M, et al. DNA/protein flow cytometry as a predictive marker of malignancy in dysplasia-free Barrett's esophagus: Thirteen-year follow-up study on a cohort of patients. Cytometry 1998;34:257-63.
27. Bani-Hani K, Martin IG, Hardie LJ, et al. Prospective study of cyclin D1 overexpression in Barrett's esophagus: Association with increased risk of adenocarcinoma. J Natl Cancer Inst 2000;92:1316-21.
28. Rudolph RE, Vaughan TL, Storer BE, et al. Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med 2000;132:612-20.
29. Bhargava P, Eisen GM, Holterman DA, et al. Endoscopic mapping and surrogate markers for better surveillance in Barrett esophagus - a study of 700 biopsy specimens. Am J Clin Pathol 2000;114:552-63.
30. Reid BJ, Prevo LJ, Galipeau PC, et al. Predictors of progression in Barrett's esophagus II: Baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 2001;96:2839-48.
31. Rabinovitch PS, Longton G, Blount PL, et al. Predictors of progression in Barrett's esophagus III: Baseline flow cytometric variables. Am J Gastroenterol 2001;96:3071-83.
32. Falk GW, Ours TM, Richter JE. Practice patterns for surveillance of Barrett's esophagus in the United States. Gastrointest Endosc 2000;52:197-203.
33. Cruz-Correa M, Gross CP, Canto MI, et al. The impact of practice guidelines in the managment of Barrett's esophagus. Arch Intern Med 2001;161:2588-95.
34. Lin OS, Mannava S, Hwang KL, et al. Reasons for current practices in managing Barrett's esophagus. Dis Esophagus 2002;15:39-45.
35. SNOMED international: The systematized nomenclature of Human and Veterinary Medicine, 3rd Ed. Northfield, IL: College of American Pathologists; 1993.
36. Dominitz JA, Maynard C, Boyko EJ. Assessment of vital status in Department of Veterans Affairs National Databases. Comparison with state death certificates. Ann Epidemiol 2001;11:286-91.
37. Guindi M, Riddell RH. Dysplasia in barrett's esophagus. New techniques and markers. Chest Surg Clin N Am 2002;12:59-68.
38. Dulai GS. Surveying the case for surveillance. Gastroenterology 2002;122:820-823.
39. Dulai GS, Guha S, Kahn KL, et al. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: A systematic review. Gastroenterology 2002;122:26-33.
40. Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 2002;123:461-7.
41. Rex D, Cummings O, Shaw M, et al. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 2003;125:1670-7.
42. Cameron AJ. Epidemiology of columnar-lined esophagus and adenocarcinoma. Gastroenterol Clin North Am 1997;26:487-94.
43. Reid BJ, Haggitt RC, Rubin CE, et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 1988;19:166-78.
44. Alikhan M, Rex D, Khan A, et al. Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Gastrointest Endosc 1999;50:23-6.
45. Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: A reaffirmation. Hum Pathol 2001;32:368-78.
46. Baak JP, ten Kate FJ, Offerhaus GJ, et al. Routine morphometrical analysis can improve reproducibility of dysplasia grade in Barrett's oesophagus surveillance biopsies. J Clin Pathol 2002;55:910-6.
47. Ormsby AH, Petras RE, Henricks WH, et al. Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut 2002;51:671-6.
48. Kim SL, Waring JP, Spechler SJ, et al. Diagnostic inconsistencies in Barrett's esophagus. Department of Veterans Affairs Gastroesophageal Reflux Study Group. Gastroenterology 1994;107:945-9.
49. Ofman JJ, Shaheen NJ, Desai AA, et al. The quality of care in Barrett's esophagus: Endoscopist and pathologist practices. Am J Gastroenterol 2001;96:876-81.
50. Ofman JJ, Lewin K, Ramers C, et al. The economic impact of the diagnosis of dysplasia in Barrett's esophagus (in process citation). Am J Gastroenterol 2000;95:2946-52.